[go: up one dir, main page]

NO20060114L - Naphthylene derivatives as cytochrome P450 inhibitors - Google Patents

Naphthylene derivatives as cytochrome P450 inhibitors

Info

Publication number
NO20060114L
NO20060114L NO20060114A NO20060114A NO20060114L NO 20060114 L NO20060114 L NO 20060114L NO 20060114 A NO20060114 A NO 20060114A NO 20060114 A NO20060114 A NO 20060114A NO 20060114 L NO20060114 L NO 20060114L
Authority
NO
Norway
Prior art keywords
cytochrome
inhibitors
treatment
naphthylene
derivatives
Prior art date
Application number
NO20060114A
Other languages
Norwegian (no)
Inventor
Vanessa Smith
Anthony Nigro
Mark Mulvihill
Cara Cesario
Patrica Anne Beck
Arlindo L Castelhano
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of NO20060114L publication Critical patent/NO20060114L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Forbindelser med formel og farmasøytisk akseptable salter derav, hvor ni, n2, n3, n4, G\ Q\ Z, R\ R', R', R'^ R'', R'^ og R'" er definert her, hemmer cytokrom P450RAI-enzymet og er anvendehge for behandling og/eller forebygging av forskjellige sykdommer og hdelser som responderer på behandling med retinoider og med naturlig forekommende retinsyre.Compounds of formula and pharmaceutically acceptable salts thereof, wherein ni, n2, n3, n4, G \ Q \ Z, R \ R ', R', R ', R' ', R' 'and R' 'are defined herein, inhibits the cytochrome P450RAI enzyme and is useful for the treatment and / or prevention of various diseases and diseases that respond to treatment with retinoids and with naturally occurring retinoic acid.

NO20060114A 2003-07-10 2006-01-06 Naphthylene derivatives as cytochrome P450 inhibitors NO20060114L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10
PCT/US2004/022282 WO2005007631A1 (en) 2003-07-10 2004-07-12 Naphthylene derivatives as cytochrome p450 inhibitors

Publications (1)

Publication Number Publication Date
NO20060114L true NO20060114L (en) 2006-02-09

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060114A NO20060114L (en) 2003-07-10 2006-01-06 Naphthylene derivatives as cytochrome P450 inhibitors

Country Status (15)

Country Link
EP (1) EP1654236A1 (en)
JP (1) JP4832295B2 (en)
KR (1) KR20060052799A (en)
CN (1) CN1819996B (en)
AU (1) AU2004257257B2 (en)
BR (1) BRPI0412424A (en)
CA (1) CA2532078A1 (en)
IL (1) IL172812A0 (en)
IS (1) IS8223A (en)
MX (1) MXPA06000401A (en)
NO (1) NO20060114L (en)
RU (1) RU2363696C2 (en)
SG (1) SG144941A1 (en)
UA (1) UA87822C2 (en)
WO (1) WO2005007631A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058301A1 (en) * 2003-12-17 2005-06-30 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
CA2800664C (en) 2010-06-01 2019-09-24 Angion Biomedica Corp. Benzothiazole cytochrome p450 inhibitors and therapeutic uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
KR20180039185A (en) * 2010-11-13 2018-04-17 이노크린 파마슈티컬즈, 인크. Metalloenzyme inhibitor compounds
EA201390876A1 (en) * 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. METALLIC ENZYME INHIBITING COMPOUNDS
CN102586187A (en) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 In vitro preservation method and culture medium for neutrophils
US20160038490A1 (en) * 2012-07-18 2016-02-11 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
HUE055262T2 (en) 2014-08-11 2021-11-29 Angion Biomedica Corp Cytochrome p450 inhibitors and uses thereof
CN104523967B (en) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 A kind of Bai Ai capsules as CYP enzyme inhibitors application
AU2015374231B2 (en) 2014-12-31 2020-07-23 Angion Biomedica Corp. Methods and agents for treating disease
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (en) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonyl-methyl)-vinyl]-imidazo-[4,5-b] pyridine derivatives and related compounds as pesticides in plant protection
AU2018207776B2 (en) 2017-01-10 2021-06-17 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
AR113206A1 (en) 2017-01-10 2020-02-19 Bayer Cropscience Ag HETEROCYCLIC DERIVATIVES AS PESTICIDES
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections
CN116903531A (en) * 2023-07-21 2023-10-20 上海中医药大学 Inhibitors of cytochrome P450 enzyme 3A4 and preparation methods and applications thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (en) * 1960-05-04
NL131915C (en) * 1966-07-27
DE3508903A1 (en) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt NEW 3-PYRIDYLMETHYLNAPHTYL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
DE3628545A1 (en) * 1985-09-23 1987-04-23 Hoechst Ag ARYLMETHYLAZOLES AND THEIR SALTS, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING THEM AND THEIR USE
WO1994008973A1 (en) * 1992-10-21 1994-04-28 Sankyo Company, Limited Azole compound
AU731272B2 (en) * 1997-11-28 2001-03-29 Lg Chemical Ltd. Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
JP4546589B2 (en) * 1998-04-23 2010-09-15 武田薬品工業株式会社 Naphthalene derivatives
CA2328973A1 (en) * 1998-04-23 1999-10-28 Akio Ojida Naphthalene derivatives, their production and use
FR2796070B1 (en) * 1999-07-06 2003-02-21 Lipha BENZODIAZEPINES DERIVATIVES FOR USE IN THE TREATMENT OF DYSLIPIDEMIA, ATHEROSCLEROSIS AND DIABETES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF PREPARATION
JP4520012B2 (en) * 1999-10-22 2010-08-04 武田薬品工業株式会社 1-Substituted-1- (1H-imidazol-4-yl) methanols
PE20010781A1 (en) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd COMPOUNDS 1- (1H-IMIDAZOL-4-IL) -1- (NAFTIL-2-SUBSTITUTED) ETHANOL, ITS PRODUCTION AND USE

Also Published As

Publication number Publication date
WO2005007631A1 (en) 2005-01-27
AU2004257257B2 (en) 2011-05-12
BRPI0412424A (en) 2006-09-05
RU2006103996A (en) 2006-07-10
CN1819996B (en) 2010-10-27
EP1654236A1 (en) 2006-05-10
JP4832295B2 (en) 2011-12-07
KR20060052799A (en) 2006-05-19
RU2363696C2 (en) 2009-08-10
CA2532078A1 (en) 2005-01-27
MXPA06000401A (en) 2006-03-17
CN1819996A (en) 2006-08-16
JP2007523866A (en) 2007-08-23
AU2004257257A1 (en) 2005-01-27
SG144941A1 (en) 2008-08-28
IS8223A (en) 2006-01-10
IL172812A0 (en) 2006-06-11
UA87822C2 (en) 2009-08-25

Similar Documents

Publication Publication Date Title
NO20060114L (en) Naphthylene derivatives as cytochrome P450 inhibitors
NO20054852L (en) GFAT inhibitors
NO20071042L (en) 5-Substituted 2-phenylaminobenzamides as MEK inhibitors
NO20070295L (en) New CIS imidazolines
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
EA200800006A1 (en) TRIAZOLOPIRIDIN AS AN INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I
NO20081942L (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
JO2282B1 (en) Oxazol derivatives
DE602007014186D1 (en) TRIAZIN-11-BETA-HYDROXYSTEROID DEHYDROGENASE ARTIFICIAL HEMMER
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
NO20090025L (en) Pyrrolotriazinkinaseinhibitorer
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
IS2696B (en) Substituted 2-aminotetraline for the treatment of depression
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20082159L (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
DE60107820D1 (en) NEW USE OF PHENYLHETEROALKYLAMINE DERIVATIVES
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
BR0313407A (en) New use of benzothiazole derivatives
SE0301232D0 (en) Novel use
NO20092035L (en) Thiazolyl compounds useful as kinase inhibitors
AU2002215932A1 (en) Nitroderivatives as drugs for diseases having an inflammatory basis
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
WO2008008701A3 (en) Substituted cyclopentane derivatives as therapeutic agents
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
NO20065873L (en) 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxoazolidin-2-one derivatives as MAO inhibitors in the treatment of bacterial infections

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application